JP2022517809A5 - - Google Patents
Info
- Publication number
- JP2022517809A5 JP2022517809A5 JP2021541292A JP2021541292A JP2022517809A5 JP 2022517809 A5 JP2022517809 A5 JP 2022517809A5 JP 2021541292 A JP2021541292 A JP 2021541292A JP 2021541292 A JP2021541292 A JP 2021541292A JP 2022517809 A5 JP2022517809 A5 JP 2022517809A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- amino acid
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794064P | 2019-01-18 | 2019-01-18 | |
| US62/794,064 | 2019-01-18 | ||
| PCT/CA2020/050042 WO2020146946A1 (en) | 2019-01-18 | 2020-01-16 | Lilrb3-binding molecules and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517809A JP2022517809A (ja) | 2022-03-10 |
| JP2022517809A5 true JP2022517809A5 (enExample) | 2023-01-26 |
| JP7631203B2 JP7631203B2 (ja) | 2025-02-18 |
Family
ID=71612981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541292A Active JP7631203B2 (ja) | 2019-01-18 | 2020-01-16 | Ｌｉｌｒｂ３結合分子とその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12404327B2 (enExample) |
| EP (1) | EP3911680A4 (enExample) |
| JP (1) | JP7631203B2 (enExample) |
| KR (1) | KR20210118116A (enExample) |
| CN (1) | CN113454123A (enExample) |
| AU (1) | AU2020209367A1 (enExample) |
| BR (1) | BR112021014102A2 (enExample) |
| CA (1) | CA3126295A1 (enExample) |
| EA (1) | EA202192008A1 (enExample) |
| IL (1) | IL284781A (enExample) |
| MX (1) | MX2021008507A (enExample) |
| SG (1) | SG11202107663UA (enExample) |
| TW (1) | TWI852980B (enExample) |
| WO (1) | WO2020146946A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI832183B (zh) * | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
| CN116963747A (zh) * | 2020-12-03 | 2023-10-27 | 德克萨斯大学体系董事会 | 用于鉴定lilrb阻断抗体的方法 |
| EP4255451A4 (en) * | 2020-12-03 | 2025-01-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
| CN115925941B (zh) * | 2022-06-08 | 2026-04-03 | 北京科诺信诚科技有限公司 | 靶向人lilrb4的纳米抗体及其应用 |
| WO2025231127A1 (en) * | 2024-05-02 | 2025-11-06 | The Regents Of The University Of California | Compositions and methods for intracellular antigen targeting with antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| JP5947727B2 (ja) | 2010-01-20 | 2016-07-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節 |
| AU2011207253B2 (en) * | 2010-01-20 | 2015-02-12 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
| AU2013234046B2 (en) | 2012-03-16 | 2017-09-07 | University Health Network | Methods and compositions for modulating Toso activity |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| CA2917077A1 (en) | 2013-07-03 | 2015-01-08 | University Health Network | Antibodies to toso |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| EP3256163A4 (en) * | 2015-02-11 | 2018-10-10 | University Health Network | Methods and compositions for modulating lilr proteins |
| CN107660150B (zh) * | 2015-03-05 | 2023-10-24 | Ab2生物股份有限公司 | Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 |
| CA3218106A1 (en) * | 2015-03-06 | 2016-09-15 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| US11787858B2 (en) * | 2016-12-22 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB3 antibodies and methods of use thereof |
-
2020
- 2020-01-16 EP EP20741290.9A patent/EP3911680A4/en active Pending
- 2020-01-16 EA EA202192008A patent/EA202192008A1/ru unknown
- 2020-01-16 AU AU2020209367A patent/AU2020209367A1/en not_active Abandoned
- 2020-01-16 US US17/421,705 patent/US12404327B2/en active Active
- 2020-01-16 SG SG11202107663UA patent/SG11202107663UA/en unknown
- 2020-01-16 BR BR112021014102-2A patent/BR112021014102A2/pt not_active Application Discontinuation
- 2020-01-16 WO PCT/CA2020/050042 patent/WO2020146946A1/en not_active Ceased
- 2020-01-16 JP JP2021541292A patent/JP7631203B2/ja active Active
- 2020-01-16 MX MX2021008507A patent/MX2021008507A/es unknown
- 2020-01-16 TW TW109101527A patent/TWI852980B/zh active
- 2020-01-16 KR KR1020217026164A patent/KR20210118116A/ko not_active Ceased
- 2020-01-16 CN CN202080015060.4A patent/CN113454123A/zh active Pending
- 2020-01-16 CA CA3126295A patent/CA3126295A1/en active Pending
-
2021
- 2021-07-12 IL IL284781A patent/IL284781A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240425617A1 (en) | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies | |
| US20260115254A1 (en) | Immune-cell targeted bispecific chimeric proteins and uses thereof | |
| TWI890481B (zh) | 雙特異性抗體 | |
| CA3095310A1 (en) | Bi-functional proteins and construction thereof | |
| WO2018141964A1 (en) | Targeted chimeric proteins and uses thereof | |
| US20140199299A1 (en) | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists | |
| JP2011509245A5 (enExample) | ||
| MX2010013239A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
| MX2014008101A (es) | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17. | |
| US12410225B2 (en) | Modulation of dendritic cell lineages | |
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2022522815A5 (enExample) | ||
| JP2022528005A5 (enExample) | ||
| JP2018500924A (ja) | 抗ｐｄ−１抗体 | |
| CA3215204A1 (en) | Il-2 based constructs | |
| TW201734041A (zh) | 抗ｉｌ-１７ｃ抗體 | |
| TWI862565B (zh) | 雙特異性抗體 | |
| RS66193B1 (sr) | Anti-pd-1 antitela | |
| JP2024544936A5 (enExample) | ||
| JP2023512827A5 (enExample) | ||
| AU2020353660A1 (en) | PD-L1 targeted chimeric proteins and uses thereof | |
| SG194362A1 (en) | Composition for treating disease | |
| JP2016512525A5 (enExample) | ||
| EP3974445A1 (en) | Bispecific molecule, and preparation and use thereof | |
| JP2022520817A5 (enExample) |